[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 30
1. Dăguci L, Simionescu C, Stepan A, Munteanu C, Dăguci C, Bătăiosu M: Warthin tumor--morphological study of the stromal compartment. Rom J Morphol Embryol; 2011;52(4):1319-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warthin tumor--morphological study of the stromal compartment.
  • Warthin tumor is the second most common benign tumors of the parotid gland, after pleomorphic adenoma.
  • Our study was performed on 21 cases with Warthin tumor diagnosed between 2005-2010, which were analyzed clinically, histologically and immunohistochemically, using anti-CD20 and anti-CD45RO antibodies.
  • The analysis of age distribution within the investigated cases indicated that Warthin tumor incidence is increasing in the seventh decade of life, most patients being male (M/F 5/2).
  • [MeSH-major] Adenolymphoma / pathology. Cell Compartmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22203940.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


2. La Perle KM, Kim DC, Hall NC, Bobbey A, Shen DH, Nagy RS, Wakely PE Jr, Lehman A, Jarjoura D, Jhiang SM: Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid; 2013 Aug;23(8):1029-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most ductal salivary gland tumors did not express NIS.
  • However, Warthin's tumors of striated duct origin exhibited consistent and intense NIS staining, corresponding with radioactive iodine uptake.
  • NIS expression in salivary glands is decreased during inflammation and tumor formation.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):382-6 [10526253.001]
  • [Cites] Aging (Milano). 1998 Oct;10(5):421-8 [9932146.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1010-4 [15754731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1187-94 [15990024.001]
  • [Cites] Nutr Health. 2009;20(2):119-34 [19835108.001]
  • [Cites] Differentiation. 2010 Feb;79(2):120-30 [20056310.001]
  • [Cites] Oral Dis. 2011 Mar;17(2):154-61 [21029259.001]
  • [Cites] Med Phys. 2011 Oct;38(10):5412-9 [21992360.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4178-84 [10566669.001]
  • [Cites] Ear Nose Throat J. 2000 Jun;79(6):460-8 [10893838.001]
  • [Cites] Thyroid. 2003 Mar;13(3):265-71 [12729475.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):179-83 [8271043.001]
  • [Cites] Nucl Med Commun. 1995 Aug;16(8):706-9 [7491186.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):43-6 [9443737.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4416-9 [9751526.001]
  • [Cites] J Dent. 2005 Mar;33(3):223-33 [15725522.001]
  • (PMID = 23441638.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA124570; United States / NCI NIH HHS / CA / P01 CA124570; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Symporters; 0 / sodium-iodide symporter
  • [Other-IDs] NLM/ PMC3752512
  •  go-up   go-down


3. Mohammadi Ghahhari N, Mohammadi Ghahhari H, Kadivar M: GSK3β and CREB3 gene expression profiling in benign and malignant salivary gland tumors. Iran Biomed J; 2012;16(3):140-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSK3β and CREB3 gene expression profiling in benign and malignant salivary gland tumors.
  • BACKGROUND: Salivary gland tumors (SGT) are rare lesions with uncertain histopathology.
  • One of the major signaling pathways that participate in the development of several tumors is protein kinase A.
  • In this pathway, glycogen synthase kinase β (GSK3β) and cAMP responsive element binding protein (CREB3) are two genes which are supposed to be down regulated in most human tumors.
  • The expression level of the genes was evaluated in SGT to scrutinize their possible under expression in these tumors.
  • METHODS: Forty eight fresh tissue samples were obtained from patients with benign and malignant SGT, including pleomorphic adenoma, warthin's tumor, mucoepidermoid carcinoma (MEC), salivary duct carcinoma and carcinoma ex pleomorphic adenoma.
  • CONCLUSION: GSK3β down regulation has been reported in many human tumors.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2000 Aug;50(8):603-9 [10972857.001]
  • [Cites] Infect Immun. 2011 Aug;79(8):3302-8 [21576335.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5548-56 [12165853.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):533-8 [12479271.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):12-4 [14657655.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):180-90 [15269293.001]
  • [Cites] Mol Cell. 2005 Jul 22;19(2):159-70 [16039586.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2005 Jun;25(3):153-60 [16450770.001]
  • [Cites] Acta Oncol. 2006;45(6):662-8 [16938808.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Mar;46(3):215-25 [17171686.001]
  • [Cites] Oral Oncol. 2007 Feb;43(2):130-6 [16857410.001]
  • [Cites] Int J Oncol. 2008 May;32(5):1041-7 [18425330.001]
  • [Cites] Mol Cell Biol. 2008 Jun;28(12):3952-66 [18391022.001]
  • [Cites] Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51 [18718806.001]
  • [Cites] Cancer Lett. 2009 Jan 18;273(2):194-200 [18606491.001]
  • [Cites] Br J Pharmacol. 2009 Mar;156(6):885-98 [19366350.001]
  • [Cites] BMC Cancer. 2009;9:247 [19622142.001]
  • [Cites] Cancer Cell. 2010 Jun 15;17(6):597-608 [20541704.001]
  • [Cites] Mol Cancer. 2010;9:144 [20537194.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1219-32 [11579131.001]
  • (PMID = 23023215.001).
  • [ISSN] 2008-823X
  • [Journal-full-title] Iranian biomedical journal
  • [ISO-abbreviation] Iran. Biomed. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / CREB3 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; EC 2.7.11.1 / GSK3B protein, human; EC 2.7.11.1 / Glycogen Synthase Kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 2.7.7.- / RNA Polymerase II
  • [Other-IDs] NLM/ PMC3629933
  • [Keywords] NOTNLM ; Gene expression profiling / Salivary Gland neoplasms / glycogen synthase kinase 3 beta / CREB3 protein
  •  go-up   go-down


Advertisement
4. Kikuchi M, Koyasu S, Shinohara S, Imai Y, Hino M, Naito Y: Preoperative Diagnostic Strategy for Parotid Gland Tumors Using Diffusion-Weighted MRI and Technetium-99m Pertechnetate Scintigraphy: A Prospective Study. PLoS One; 2016;11(2):e0148973
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative Diagnostic Strategy for Parotid Gland Tumors Using Diffusion-Weighted MRI and Technetium-99m Pertechnetate Scintigraphy: A Prospective Study.
  • OBJECTIVE: Fine needle aspiration cytology (FNAC) for diagnosis of a parotid gland tumor is widely used but its sensitivity is low and non-diagnostic rate is relatively high.
  • Screening of patients with parotid gland tumors to identify cases of pleomorphic adenoma (PA) and Warthin tumor (WT) may allow CNB to be confined to patients without PA and WT.
  • We established an algorithm for preoperative diagnosis and management of parotid gland tumor using diffusion-weighted MRI and 99mTc pertechnetate scintigraphy.
  • METHODS: A prospective study was conducted in 71 cases who were newly diagnosed with parotid gland tumor and 53 cases were enrolled in the study.
  • RESULTS: Although CNB was only required in 40% (21/53) of all cases, we made a preoperative histopathological diagnosis with an accuracy of 87% (46/53) and we correctly diagnosed whether a tumor was benign or malignant with an accuracy of 96% (51/53).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):121-6 [15665697.001]
  • [Cites] Korean J Radiol. 2013 Mar-Apr;14(2):299-306 [23482651.001]
  • [Cites] Laryngoscope. 2013 Dec;123(12):3056-60 [23798340.001]
  • [Cites] Laryngoscope. 2014 Mar;124(3):695-700 [23929672.001]
  • [Cites] Acta Otolaryngol. 2014 Nov;134(11):1185-91 [25315918.001]
  • [Cites] Eur Radiol. 2014 Dec;24(12):3088-96 [25117744.001]
  • [Cites] Int J Oral Maxillofac Surg. 2015 Feb;44(2):151-7 [25457828.001]
  • [Cites] Am J Otolaryngol. 2014 Nov-Dec;35(6):713-8 [25128908.001]
  • [Cites] Radiology. 2001 Dec;221(3):837-42 [11719687.001]
  • [Cites] Eur Radiol. 2001;11(12):2472-8 [11734943.001]
  • [Cites] Head Neck. 2013 Nov;35(11):1657-61 [23109044.001]
  • [Cites] Cancer. 2004 May 1;100(9):1876-83 [15112268.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Aug;25(7):1256-62 [15313720.001]
  • [Cites] J Oral Surg. 1981 May;39(5):362-6 [6938654.001]
  • [Cites] Laryngoscope. 1983 Jun;93(6):695-716 [6304434.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):179-83 [8271043.001]
  • [Cites] South Med J. 1997 Apr;90(4):416-8 [9114834.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):506-12 [16012309.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(11):1213-7 [17050316.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jan;28(1):116-21 [17213436.001]
  • [Cites] Acta Radiol. 2007 Nov;48(9):980-7 [17957512.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jan;29(1):40-4 [17921228.001]
  • [Cites] J Neuroradiol. 2008 May;35(2):71-8 [18325591.001]
  • [Cites] Radiology. 2008 Dec;249(3):909-16 [18941162.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Mar;30(3):591-6 [19131405.001]
  • [Cites] Radiology. 2009 Oct;253(1):144-52 [19789257.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 2010 May;113(5):441-9 [20560405.001]
  • [Cites] AJR Am J Roentgenol. 2011 May;196(5):1160-3 [21512086.001]
  • [Cites] AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):1100-6 [21393402.001]
  • [Cites] Am J Clin Pathol. 2011 Jul;136(1):45-59 [21685031.001]
  • [Cites] Int J Oral Maxillofac Surg. 2012 Apr;41(4):437-43 [22204925.001]
  • [Cites] J Neurosurg. 2012 Dec;117 Suppl:63-8 [23205791.001]
  • [Cites] Clin Imaging. 2013 Mar-Apr;37(2):232-8 [23465973.001]
  • [Cites] Head Neck. 2005 Mar;27(3):217-23 [15672359.001]
  • (PMID = 26849569.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] A0730CX801 / Sodium Pertechnetate Tc 99m
  • [Other-IDs] NLM/ PMC4744013
  •  go-up   go-down


5. Kehagias N, Epivatianos A, Sakas L, Andreadis D, Markopoulos A, Antoniades K: Expression of N-cadherin in salivary gland tumors. Med Princ Pract; 2013;22(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of N-cadherin in salivary gland tumors.
  • OBJECTIVE: To detect immunohistochemically the N-cadherin expression in different types of benign and malignant salivary gland tumors in an attempt to note any possible correlation to their development, stage and invasive properties.
  • MATERIALS AND METHODS: N-cadherin expression was examined in tissue specimens from 49 salivary gland tumors including: pleomorphic adenomas (4), Warthin's tumors (10), and myoepitheliomas (4) (benign tumors), as well as adenoid cystic carcinomas (14), mucoepidermoid carcinomas (4), polymorphous low-grade adenocarcinomas (6), and adenocarcinomas not otherwise specified (5) (malignant tumors).
  • The perineural invasion and stage of malignant salivary gland tumors were evaluated.
  • In benign salivary gland tumors, N-cadherin along membranes of neoplastic cells as well as in centrocytes of lymphoid germinal centers was seen in 1 and 4 cases of Warthin's tumors, respectively.
  • Varied degree of N-cadherin expression was found in 13 (45%) cases of malignant salivary gland tumors.
  • N-cadherin expression was significantly correlated with perineural invasion (χ(2) = 11.7, p < 0.0001), but not with stage of malignant salivary gland tumors.
  • CONCLUSION: N-cadherin expression was observed in malignant salivary gland tumors and could be an indicator of potentially aggressive behavior.
  • N-cadherin expression by tumor cells could be attributed to perineural invasion.
  • [MeSH-minor] Biomarkers, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 S. Karger AG, Basel.
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Cardiovasc Res. 2001 Dec;52(3):372-86 [11738054.001]
  • [Cites] Hum Pathol. 1999 Sep;30(9):1035-9 [10492037.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):301-14 [12398894.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 2):2649-58 [3539943.001]
  • [Cites] J Cell Biol. 1977 Nov;75(2 Pt 1):464-74 [264120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(9):2789-93 [3857614.001]
  • [Cites] Dev Dyn. 2002 Jul;224(3):321-33 [12112462.001]
  • [Cites] Oral Dis. 2005 May;11(3):175-80 [15888109.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Apr;16(4):451-65 [17371194.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7003-11 [18056176.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Cell Sci. 2008 Mar 15;121(Pt 6):727-35 [18322269.001]
  • [Cites] Biol Pharm Bull. 2004 Dec;27(12):1891-4 [15577201.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):225-35 [16258702.001]
  • [Cites] Immunol Rev. 2010 Sep;237(1):72-89 [20727030.001]
  • [Cites] J Oral Pathol Med. 2003 May;32(5):297-304 [12694354.001]
  • [Cites] J Laryngol Otol. 2006 Apr;120(4):298-304 [16623973.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):631-44 [10545506.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):355-8 [9199196.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):779-90 [10684258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4246-50 [2349235.001]
  • [Cites] J Cell Biol. 1989 Jun;108(6):2435-47 [2661563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 May 24;108(21):8755-60 [21555569.001]
  • [Cites] EMBO J. 1988 Dec 1;7(12):3679-84 [3061804.001]
  • (PMID = 22738870.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


6. Jo HJ, Ahn HJ, Jung S, Yoon HK: Diagnostic difficulties in fine needle aspiration of benign salivary glandular lesions. Korean J Pathol; 2012 Dec;46(6):569-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: There were 77 cases of benign salivary lesions, consisting of pleomorphic adenoma (PA) in 61 cases, Warthin's tumor (WT) in 12 cases, and other benign lesions in 4 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23323108.001).
  • [ISSN] 1738-1843
  • [Journal-full-title] Korean journal of pathology
  • [ISO-abbreviation] Korean J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3540335
  • [Keywords] NOTNLM ; Benign lesion / Biopsy, fine-needle / Salivary glands
  •  go-up   go-down


7. Yan B, Li B, Wen Z, Luo X, Xue L, Li L: Label-free blood serum detection by using surface-enhanced Raman spectroscopy and support vector machine for the preoperative diagnosis of parotid gland tumors. BMC Cancer; 2015;15:650
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Label-free blood serum detection by using surface-enhanced Raman spectroscopy and support vector machine for the preoperative diagnosis of parotid gland tumors.
  • METHODS: The blood serums were collected from four groups: the patients with pleomorphic adenoma, the patients with Warthin's tumor, the patients with mucoepidermoid carcinoma and the volunteers without parotid gland neoplasms.
  • RESULTS: It was demonstrated that there were different intensities of SERS peaks assigned to various biochemical changes in the blood serum between the parotid gland tumor groups and normal control group.
  • Compared with the SERS spectra of the normal serums, the intensities of peaks assigned to nucleic acids and proteins increased in the SERS spectra of the parotid gland tumor serums, which manifested the differences of the biochemical metabolites in the serum from the patients with parotid gland tumors.
  • Though the accuracy, sensitivity and specificity decreased in the leave-one-patient-out cross validation, the mucoepidermoid carcinoma was still easier to diagnose than other tumors.
  • DISCUSSION: The specific molecular differences of parotid gland tumors and normal serums were significantly demonstrated through the comparison between the various SERS spectra.But compared with the serum SERS spectra reported in the other studies, some differences exist between the spectra in this study and the ones reported in the lietratures.
  • These differences may result from the various nano-particles, the different preparation of serum and equipment parameters, and we could need a further research to find an exact explanation.Based on the SERS spectra of the serum samples, SVM have shown a giant potential to diagnose the parotid gland tumors in our preliminary study.
  • CONCLUSIONS: This exploratory research demonstrated the great potential of SERS combined with SVM into a non-invasive clinical diagnostic method for preoperative diagnosis of parotid gland tumors.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 1999 Dec;28(6):441-4 [10609745.001]
  • [Cites] Head Neck. 2015 Apr;37(4):511-7 [24677300.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Aug;261(7):369-75 [14586626.001]
  • [Cites] J Chem Inf Comput Sci. 2004 Nov-Dec;44(6):2040-6 [15554673.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):203-7 [15720991.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):267-76 [15894488.001]
  • [Cites] Clin Chim Acta. 2006 Oct;372(1-2):83-93 [16730689.001]
  • [Cites] Biopolymers. 2008 Mar;89(3):235-41 [18041066.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):785-98 [18203445.001]
  • [Cites] Head Neck Oncol. 2009;1:34 [19761601.001]
  • [Cites] Appl Spectrosc. 2009 Oct;63(10):1089-94 [19843357.001]
  • [Cites] Biosens Bioelectron. 2010 Jul 15;25(11):2414-9 [20427174.001]
  • [Cites] Head Neck Oncol. 2010;2:26 [20923567.001]
  • [Cites] Biochim Biophys Acta. 2010 Dec;1806(2):200-7 [20637263.001]
  • [Cites] Biosens Bioelectron. 2011 Mar 15;26(7):3167-74 [21227679.001]
  • [Cites] Oral Oncol. 2011 May;47(5):430-5 [21439894.001]
  • [Cites] Opt Express. 2011 Jul 4;19(14):13565-77 [21747512.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2011 Sep;79(5):915-9 [21622021.001]
  • [Cites] Nanomedicine. 2011 Oct;7(5):655-63 [21333756.001]
  • [Cites] Lung Cancer. 2011 Nov;74(2):206-11 [21529985.001]
  • [Cites] Cancer Res. 2012 May 15;72(10):2491-500 [22434431.001]
  • [Cites] Anal Chim Acta. 2013 Jan 14;760:25-33 [23265730.001]
  • [Cites] Biotechnol J. 2013 Mar;8(3):288-97 [23161832.001]
  • [Cites] Lasers Med Sci. 2014 Mar;29(2):723-8 [23893093.001]
  • [Cites] Sci Rep. 2014;4:4751 [24756153.001]
  • [Cites] Lasers Surg Med. 2003;32(3):210-4 [12605428.001]
  • (PMID = 26438216.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC4595250
  •  go-up   go-down


8. Wang YL, Zhu YX, Chen TZ, Wang Y, Sun GH, Zhang L, Huang CP, Wang ZY, Shen Q, Li DS, Wu Y, Ji QH: Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: experience of one cancer center 1997-2007. Acta Otolaryngol; 2012 Aug;132(8):879-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: experience of one cancer center 1997-2007.
  • Comprehensive use of diagnostic modalities, neck dissection, and postoperative radiation will improve the treatment results for salivary gland tumors (SGTs).
  • Pleomorphic adenoma and Warthin's tumor were the most common types of SGT.
  • The percentage of tumors by pathologic TNM stage were 23.7% for stage I, 32.9% for stage II, 17.3% for stage III, and 26.1% for stage IV.

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Mar;259(3):146-9 [12003266.001]
  • [Cites] Acta Otolaryngol. 2011 Nov;131(11):1226-31 [21838608.001]
  • [Cites] Head Neck. 2003 Jul;25(7):543-8 [12808657.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):1017-22 [14601064.001]
  • [Cites] Head Neck. 2005 Mar;27(3):217-23 [15672359.001]
  • [Cites] Acta Otolaryngol. 2005 Feb;125(2):207-14 [15880955.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):533-6 [16053874.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2005 Jun;25(3):182-90 [16450775.001]
  • [Cites] Ann Acad Med Singapore. 2006 Apr;35(4):242-8 [16710494.001]
  • [Cites] Diagn Cytopathol. 2006 Aug;34(8):580-4 [16850487.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul;104(1):94-100 [17577550.001]
  • [Cites] Oral Oncol. 2008 Feb;44(2):187-92 [17418612.001]
  • [Cites] Am J Otolaryngol. 2008 Mar-Apr;29(2):94-100 [18314019.001]
  • [Cites] Br J Oral Maxillofac Surg. 2008 Dec;46(8):635-8 [18620785.001]
  • [Cites] Braz J Otorhinolaryngol. 2009 Jul-Aug;75(4):497-501 [19784416.001]
  • [Cites] Acta Otolaryngol. 2010 Feb;130(2):286-92 [19544204.001]
  • [Cites] Int J Oral Maxillofac Surg. 2010 Mar;39(3):235-42 [19951834.001]
  • [Cites] Crit Rev Oncol Hematol. 2010 May;74(2):134-48 [19939701.001]
  • [Cites] Head Neck. 2010 Oct;32(10):1402-11 [20029981.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Oct;40(5):389-92 [12379184.001]
  • (PMID = 22497626.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3433083
  •  go-up   go-down


9. Smółka W, Markowski J, Piotrowska-Seweryn A, Paleń P, Dobrosz Z, Dziubdziela W: Mucoepidermoid carcinoma in Warthin tumor of the parotid gland. Arch Med Sci; 2015 Jun 19;11(3):691-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma in Warthin tumor of the parotid gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26170867.001).
  • [ISSN] 1734-1922
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC4495166
  •  go-up   go-down


10. Winter J, Pantelis A, Kraus D, Reckenbeil J, Reich R, Jepsen S, Fischer HP, Allam JP, Novak N, Wenghoefer M: Human α-defensin (DEFA) gene expression helps to characterise benign and malignant salivary gland tumours. BMC Cancer; 2012;12:465
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to define new proliferation associated genes, purpose of this study was to investigate the expression of human α-defensins (DEFA) 1/3 and 4 in different tumour entities of the salivary glands with respect to malignancy.
  • A similar expression pattern of DEFA-1/3 and -4 in cystadenolymphomas and inflamed salivary glands underlines a potential importance of immunological reactions during the formation of Warthin's tumour.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenolymphoma / genetics. Adenolymphoma / metabolism. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / genetics. Adenoma, Pleomorphic / metabolism. Analysis of Variance. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / metabolism. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Nat Rev Microbiol. 2004 Sep;2(9):727-38 [15372083.001]
  • [Cites] Nat Rev Microbiol. 2005 Mar;3(3):238-50 [15703760.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2526-33 [15900577.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):585-8 [15912361.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):964-8 [15861216.001]
  • [Cites] Pathologe. 2005 Sep;26(5):345-52 [16049672.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8542-9 [16951166.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 May;133(5):450-4 [17515503.001]
  • [Cites] Med Mol Morphol. 2007 Dec;40(4):179-84 [18085375.001]
  • [Cites] Int J Oral Maxillofac Surg. 2008 Jul;37(7):660-3 [18346877.001]
  • [Cites] BMC Cancer. 2008;8:290 [18840281.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(2):269-73 [19434322.001]
  • [Cites] Oral Oncol. 2009 Jun;45(6):526-30 [18805729.001]
  • [Cites] Cancer Invest. 2009 Jun;27(5):575-81 [19219676.001]
  • [Cites] Oral Microbiol Immunol. 2009 Oct;24(5):353-60 [19702947.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2406-12 [19745222.001]
  • [Cites] Genes Immun. 2010 Jan;11(1):45-54 [19829306.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep;110(3):351-6 [20727496.001]
  • [Cites] Cell Tissue Res. 2011 Jan;343(1):175-88 [20730446.001]
  • [Cites] J Craniofac Surg. 2011 Jan;22(1):100-4 [21187770.001]
  • [Cites] Cancer Invest. 2011 Mar;29(3):196-201 [21280982.001]
  • [Cites] Cancer Invest. 2012 Feb;30(2):106-13 [22250586.001]
  • [Cites] J Cell Physiol. 2012 Mar;227(3):994-1003 [21520074.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S401-13 [10938683.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Lab Invest. 2003 Apr;83(4):501-5 [12695553.001]
  • [Cites] Nat Rev Immunol. 2003 Sep;3(9):710-20 [12949495.001]
  • [Cites] Infect Immun. 1999 Jun;67(6):2740-5 [10338476.001]
  • (PMID = 23050799.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Defensins; 0 / human neutrophil peptide 1; 0 / human neutrophil peptide 3; 0 / human neutrophil peptide 4
  • [Other-IDs] NLM/ PMC3518101
  •  go-up   go-down






Advertisement